Osteoarthritis, Knee
Conditions
Brief summary
The goal of this clinical trial is to test low-intensity continuous ultrasound stimulator(LICUS) for patients suffering from knee arthritis. it aims to evaluate the pain relief effect of LICUS. 35 participants were recruited, treated by LICUS on the knee joint for 5 minutes, 3 times a day for 4 weeks. This study has single group and is for a before and after comparison of clinical treatment.
Detailed description
Subject: 35 osteoarthritis patients Evaluation measure: Visual Analogue Scale (VAS), McMaster Universities Osteoarthritis Index (WOMAC) Method: A total of 35 subjects were selected in consideration of the dropout rate of 20%. Selected subjects were treated as a single group without randomization, and an appropriate amount of gel was applied to the knee OA pain area for 4 weeks. A blinded evaluation at baseline and after treat-ment was made. Primary outcome was pain on movement assessed by the VAS index. Secondary outcomes consisted of the WOMAC scores.
Interventions
DEVICELow-intensity continuous ultrasound stimulator
Stimulation 5 minutes, 3 times a day for 4 weeks on the knee
Sponsors
Kyu Jae Lee
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Masking description
No need of blinding
Intervention model description
Before and after of treatment in single group
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Patients aged 40 to 60 years with pain due to OA of the knee and able to walk voluntarily * Those who have more than one osteophyte in the tibiofemoral joint on radiographic findings (Kellgren-Lawrence gradesⅡ,Ⅲ) * At visit 1 (screening) and visit 2, the pain status during knee OA activity was 100 mm pain VAS, as a result, those who are over 40mm * If the Kellgren & Lawrence Grades are the same, target the one with the higher 100mm pain VAS * Patients who are willing or able to follow the doctor's instructions, including joint movements * Persons who can comply with concomitantly permitted drugs, prohibited drugs, and relief drugs * Persons who can maintain the same exercise and activity during the clinical trial period * Fully understand the purpose and procedure of this clinical trial
Exclusion criteria
* Those who have a history of rheumatoid arthritis or gouty arthritis or who have peripheral pain other than the knee joint patient. * Those with fractures or dislocations on simple radiological examination. * Those who are identified, or those with a similar risk of neuromuscular disease * Those who have participated in other clinical trials within 6 months of participating in clinical trials. * Patients with severe pain in the knee joint other than angular deformity, instability, and index knee in the knee joint * Patients with other tumors other than degenerative knee arthrosis * Persons with systemic symptoms that may affect knee pain * Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual analogue scale(VAS) | 4 weeks | Evaluation of pain on movement assessed by the VAS index |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | 4 weeks | Evaluation of pain on movement assessed by the WOMAC |
Countries
South Korea
Outcome results
None listed